|
|
|
|
Bringing a new drug to the market is a massive undertaking, but conventional preclinical models often fail to predict human response. This failure is a major reason why 90% of drugs that pass the preclinical stage ultimately fail during human trials. However, Organ-on-a-Chip technology offers a paradigm shift in drug development.
|
|
|
|
|
Even with tremendous improvements in the study of human biology — some caused by the phenomenon Moore’s Law describes — the cost of advancing a compound through clinical trials to FDA approval continues to skyrocket. “Eroom’s Law”, coined by Economist Jack Scannell as a cheeky reversal of Moore’s Law, observes that drug development is only slowing down and getting more expensive.
|
|
|
|
|
Explore compelling evidence that suggests Organ-on-a-Chip technology offers a far more reliable means of predicting drug toxicity than traditional animal models.
|
|
|
|
|
The drug development industry recognizes the importance of predictive validity, but Jack Scannell, the author of Eroom’s law, and a team of experts argue it is even more crucial than most believe it to be.
|
|
|
|
|
For centuries, animal studies have been the cornerstone of preclinical research, offering invaluable insights into human biology and disease mechanisms. However, as science progresses, so do our tools. Enter Organ-Chips, a cutting-edge technology poised to reshape the landscape of biomedical research.
|
|
|
|
|
|
|
